Sarepta Therapeutics (SRPT) Short Interest Ratio & Short Volume $106.28 -2.13 (-1.96%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$106.22 -0.06 (-0.06%) As of 02/21/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Sarepta Therapeutics Short Interest DataSarepta Therapeutics (SRPT) has a short interest of 5.05 million shares. This marks a 1.41% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.3, indicating that it would take 5.3 days of the average trading volume of 774,033 shares to cover all short positions.Current Short Interest5,050,000 sharesPrevious Short Interest4,980,000 sharesChange Vs. Previous Month+1.41%Dollar Volume Sold Short$574.29 millionShort Interest Ratio5.3 Days to CoverLast Record DateJanuary 31, 2025Outstanding Shares95,520,000 sharesPercentage of Shares Shorted5.29%Today's Trading Volume709,268 sharesAverage Trading Volume774,033 sharesToday's Volume Vs. Average92% Short Selling Sarepta Therapeutics? Sign up to receive the latest short interest report for Sarepta Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartSRPT Short Interest Over TimeSRPT Days to Cover Over TimeSRPT Percentage of Float Shorted Over Time Sarepta Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/31/20255,050,000 shares $574.29 million +1.4%N/A5.3 $113.72 1/15/20254,980,000 shares $594.26 million -2.9%N/A5.3 $119.33 12/31/20245,130,000 shares $623.76 million -8.2%N/A5.5 $121.59 12/15/20245,590,000 shares $691.54 million -4.0%N/A5.8 $123.71 11/30/20245,820,000 shares $776.04 million +15.5%N/A6 $133.34 11/15/20245,040,000 shares $526.88 million -10.0%N/A5.5 $104.54 10/31/20245,600,000 shares $705.60 million -1.1%N/A6.6 $126.00 10/15/20245,660,000 shares $700.31 million -8.6%N/A6 $123.73 9/30/20246,190,000 shares $773.07 million +0.7%N/A6.1 $124.89 9/15/20246,150,000 shares $766.60 million -5.8%N/A5.3 $124.65 Get the Latest News and Ratings for SRPT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/20246,530,000 shares $886.64 million -3.0%N/A4.4 $135.78 8/15/20246,730,000 shares $897.38 million +0.2%N/A3.5 $133.34 7/31/20246,720,000 shares $955.85 million -8.3%N/A3.5 $142.24 7/15/20247,330,000 shares $1.12 billion -23.3%N/A3.9 $152.67 6/30/20249,560,000 shares $1.51 billion +1.1%N/A5.4 $158.00 6/15/20249,460,000 shares $1.16 billion +45.8%N/A5.7 $122.84 5/31/20246,490,000 shares $842.79 million -1.1%N/A5.1 $129.86 5/15/20246,560,000 shares $869.20 million +15.3%N/A7.3 $132.50 4/30/20245,690,000 shares $720.70 million +16.8%N/A6.2 $126.66 4/15/20244,870,000 shares $576.17 million +5.9%N/A5.8 $118.31 3/31/20244,600,000 shares $595.52 million -7.4%N/A4.5 $129.46 3/15/20244,970,000 shares $611.56 million +4.0%N/A4.6 $123.05 2/29/20244,780,000 shares $611.36 million -0.6%N/A4 $127.90 2/15/20244,810,000 shares $600.72 million -7.0%N/A4.1 $124.89 1/31/20245,170,000 shares $615.18 million -9.0%N/A4.1 $118.99 1/15/20245,680,000 shares $663.42 million +21.1%N/A3.2 $116.80 12/31/20234,690,000 shares $452.26 million -0.4%N/A2.7 $96.43 12/15/20234,710,000 shares $437.98 million +10.6%N/A2.9 $92.99 11/30/20234,260,000 shares $346.25 million +0.2%N/A2.8 $81.28 11/15/20234,250,000 shares $355.98 million -4.5%N/A2.9 $83.76 10/31/20234,450,000 shares $299.53 million -8.8%N/A3 $67.31 10/15/20234,880,000 shares $575.64 million +1.2%N/A5.4 $117.96 9/30/20234,820,000 shares $584.28 million +6.6%N/A5.2 $121.22 9/15/20234,520,000 shares $535.17 million -2.0%N/A4.6 $118.40 8/31/20234,610,000 shares $557.86 million +4.1%N/A4.3 $121.01 8/15/20234,430,000 shares $505.37 million -0.5%N/A3.8 $114.08 7/31/20234,450,000 shares $482.34 million -9.9%N/A3.2 $108.39 7/15/20234,940,000 shares $532.70 million -1.0%N/A3.5 $107.84 6/30/20234,990,000 shares $571.45 million +9.7%N/A3.3 $114.52 6/15/20234,550,000 shares $598.83 million +2.9%N/A3.1 $131.61The Real Hillbilly Elegy (Ad)The mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky, Tennessee and beyond… It's one of our country’s most scenic areas. But hidden beneath the beauty is an ugly reality: our most beautiful land is also the poorest. It’s a tragedy because for over 200 years, generation after generation has worked “coal country” with nothing but a pick and shovel, hauling billions of dollars from the ground.A bold new plan, hidden in Executive Order 14154… 5/31/20234,420,000 shares $546.31 million +17.9%N/A2.8 $123.60 5/15/20233,750,000 shares $589.46 million -8.5%N/A2.2 $157.19 4/30/20234,100,000 shares $503.36 million -8.5%N/A2.8 $122.77 4/15/20234,480,000 shares $549.38 million -5.1%N/A3.1 $122.63 3/31/20234,720,000 shares $650.56 million -13.2%N/A3.4 $137.83 3/15/20235,440,000 shares $791.36 million -32.7%N/A4 $145.47 2/28/20238,080,000 shares $986.81 million +7.0%N/A7.1 $122.13 2/15/20237,550,000 shares $941.64 million +12.4%N/A8.1 $124.72 1/31/20236,720,000 shares $839.80 million +8.9%N/A7.3 $124.97 1/15/20236,170,000 shares $781.74 million -9.8%N/A6.5 $126.70 12/30/20226,840,000 shares $886.33 million -1.0%N/A7.3 $129.58 12/15/20226,910,000 shares $861.33 million -1.0%N/A7.5 $124.65 11/30/20226,980,000 shares $857.21 million -5.0%N/A6.5 $122.81 11/15/20227,350,000 shares $806.15 million -8.6%N/A7.2 $109.68 10/31/20228,040,000 shares $916.72 million +11.1%N/A7.5 $114.02 10/15/20227,240,000 shares $814.14 million -1.4%N/A6.4 $112.45 9/30/20227,340,000 shares $811.36 million +7.6%N/A6.7 $110.54 9/15/20226,820,000 shares $754.84 million +4.1%N/A6 $110.68 8/31/20226,550,000 shares $716.44 million -4.5%N/A6.7 $109.38 8/15/20226,860,000 shares $748.01 million +34.3%N/A7.2 $109.04 7/31/20225,110,000 shares $474.97 million -4.7%N/A5.5 $92.95 7/15/20225,360,000 shares $448.04 million +2.7%N/A6.8 $83.59 6/30/20225,220,000 shares $391.29 million +4.8%N/A6.7 $74.96 6/15/20224,980,000 shares $321.21 million -0.4%N/A6.7 $64.50 5/31/20225,000,000 shares $364.10 million -2.0%N/A7 $72.82 5/15/20225,100,000 shares $336.45 million +5.6%N/A6.7 $65.97 4/30/20224,830,000 shares $349.31 million -1.2%N/A6.6 $72.32 4/15/20224,890,000 shares $398.29 million -5.4%N/A6.2 $81.45 3/31/20225,170,000 shares $403.88 million -2.5%N/A5.2 $78.12 3/15/20225,300,000 shares $403.70 million -1.1%N/A5.4 $76.17 2/28/20225,360,000 shares $410.63 million -2.2%N/A5.4 $76.61 2/15/20225,480,000 shares $445.80 million -6.8%N/A5.6 $81.35 1/31/20225,880,000 shares $420.83 million +30.1%N/A5.8 $71.57 1/15/20224,520,000 shares $321.37 million -1.3%N/A4.3 $71.10 12/31/20214,580,000 shares $412.43 million -15.0%N/A4.4 $90.05 12/15/20215,390,000 shares $470.71 million -1.1%N/A5.2 $87.33 11/30/20215,450,000 shares $440.41 million +16.5%N/A5.2 $80.81 11/15/20214,680,000 shares $392.56 million +2.0%N/A4.7 $83.88 10/29/20214,590,000 shares $363.21 million -8.8%N/A4.7 $79.13 10/15/20215,030,000 shares $423.48 million -0.2%N/A5.3 $84.19 9/30/20215,040,000 shares $466.10 million -11.0%6.7%6 $92.48 9/15/20215,660,000 shares $475.72 million -3.6%7.5%7.3 $84.05 8/31/20215,870,000 shares $458.56 million -5.0%7.8%7.5 $78.12 8/13/20216,180,000 shares $494.03 million -2.4%8.2%6.7 $79.94 7/30/20216,330,000 shares $429.05 million -2.5%8.3%6 $67.78 7/15/20216,490,000 shares $443.72 million +0.8%8.5%5.9 $68.37 6/30/20216,440,000 shares $500.65 million -3.3%8.5%5.9 $77.74 6/15/20216,660,000 shares $553.71 million -16.7%8.8%5.8 $83.14 5/28/20217,990,000 shares $604.44 million +4.0%10.5%6.9 $75.65 5/14/20217,680,000 shares $556.88 million +8.0%N/A6.6 $72.51The Real Hillbilly Elegy (Ad)The mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky, Tennessee and beyond… It's one of our country’s most scenic areas. But hidden beneath the beauty is an ugly reality: our most beautiful land is also the poorest. It’s a tragedy because for over 200 years, generation after generation has worked “coal country” with nothing but a pick and shovel, hauling billions of dollars from the ground.A bold new plan, hidden in Executive Order 14154… 4/30/20217,110,000 shares $507.73 million -2.2%N/A6.3 $71.41 4/15/20217,270,000 shares $533.84 million -0.7%N/A6.3 $73.43 3/31/20217,320,000 shares $535.09 million +7.3%N/A3.5 $73.10 3/15/20216,820,000 shares $589.73 million -6.8%N/A3.3 $86.47 2/26/20217,320,000 shares $624.03 million +8.9%N/A3.6 $85.25 2/12/20216,720,000 shares $609.97 million -13.3%N/A3.6 $90.77 1/29/20217,750,000 shares $698.51 million -4.3%N/A4.1 $90.13 1/15/20218,100,000 shares $728.19 million +14.6%N/A4.6 $89.90 12/31/20207,070,000 shares $1.21 billion -10.6%N/A5 $171.54 12/15/20207,910,000 shares $1.34 billion -9.1%N/A11.3 $169.54 11/30/20208,700,000 shares $1.21 billion +5.2%N/A12.7 $139.15 11/15/20208,270,000 shares $1.17 billion -6.2%N/A11.6 $141.40 10/30/20208,820,000 shares $1.25 billion -0.6%N/A12.1 $141.49 10/15/20208,870,000 shares $1.29 billion -2.9%N/A13.5 $145.12 9/30/20209,130,000 shares $1.28 billion +0.7%N/A13.1 $140.43 9/15/20209,070,000 shares $1.30 billion -4.1%N/A12.5 $142.80 8/31/20209,460,000 shares $1.39 billion -3.2%N/A12 $146.42 8/14/20209,770,000 shares $1.53 billion -3.0%N/A11.7 $157.00 7/31/202010,070,000 shares $1.55 billion -3.5%N/A11.4 $153.52 7/15/202010,440,000 shares $1.74 billion -2.1%14.1%11.6 $166.76 6/30/202010,660,000 shares $1.73 billion -9.9%14.4%11.7 $162.71 6/15/202011,830,000 shares $1.88 billion +1.4%16.0%12.4 $158.85 5/29/202011,670,000 shares $1.78 billion +1.0%15.8%12 $152.27 5/15/202011,560,000 shares $1.63 billion +0.3%15.6%11.8 $141.25 4/30/202011,530,000 shares $1.36 billion -2.7%15.6%13.2 $117.88 4/15/202011,850,000 shares $1.33 billion -4.6%16.0%13.4 $112.09 3/31/202012,420,000 shares $1.51 billion -1.9%16.8%13.1 $121.53 3/13/202012,659,400 shares $1.38 billion +0.6%17.2%14.5 $108.75 2/28/202012,580,000 shares $1.12 billion -0.3%17.1%11.4 $89.38 SRPT Short Interest - Frequently Asked Questions What is Sarepta Therapeutics' current short interest? Short interest is the volume of Sarepta Therapeutics shares that have been sold short but have not yet been closed out or covered. As of January 31st, investors have sold 5,050,000 shares of SRPT short. Learn More on Sarepta Therapeutics' current short interest. What is a good short interest ratio for Sarepta Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SRPT shares currently have a short interest ratio of 5.0. Learn More on Sarepta Therapeutics's short interest ratio. Which institutional investors are shorting Sarepta Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Sarepta Therapeutics: GTS Securities LLC, Wolverine Trading LLC, Squarepoint Ops LLC, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC , Millennium Management LLC, Group One Trading LLC, Caption Management LLC, Citadel Advisors LLC, BNP Paribas Financial Markets, Jane Street Group LLC, Parallax Volatility Advisers L.P., Susquehanna International Group LLP, Hsbc Holdings PLC, Concourse Financial Group Securities Inc., PEAK6 LLC, Walleye Trading LLC, Walleye Capital LLC, Barclays PLC, JPMorgan Chase & Co., Simplex Trading LLC, Twin Tree Management LP, Wolverine Asset Management LLC, and JPMorgan Chase & Co.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Sarepta Therapeutics' short interest increasing or decreasing? Sarepta Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 5,050,000 shares, an increase of 1.4% from the previous total of 4,980,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Sarepta Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Sarepta Therapeutics: argenx SE (3.32%), BioNTech SE (1.14%), Teva Pharmaceutical Industries Limited (1.97%), Summit Therapeutics Inc. (2.83%), Genmab A/S (0.26%), Intra-Cellular Therapies, Inc. (1.50%), Viatris Inc. (2.60%), Moderna, Inc. (11.84%), Dr. Reddy's Laboratories Limited (1.90%), Vaxcyte, Inc. (10.86%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks. What does it mean to sell short Sarepta Therapeutics stock? Short selling SRPT is an investing strategy that aims to generate trading profit from Sarepta Therapeutics as its price is falling. SRPT shares are trading down $2.13 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Sarepta Therapeutics? A short squeeze for Sarepta Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SRPT, which in turn drives the price of the stock up even further. How often is Sarepta Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SRPT, twice per month. The most recent reporting period available is January, 31 2025. More Short Interest Resources from MarketBeat Related Companies ARGX Short Interest BNTX Short Interest TEVA Short Interest SMMT Short Interest GMAB Short Interest ITCI Short Interest VTRS Short Interest MRNA Short Interest RDY Short Interest PCVX Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SRPT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
